Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.
Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...
The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...
Our initial experience with the DurAVR ® THV System has been very positive, and we look forward to providing definitive comparative evidence which could transform patient care.” “With the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback